HUMA (Humacyte, NASDAQ) pre-market 23 Mar 2026: earnings on Mar 27 could reset HUMA stock

Humacyte, Inc. (HUMA) trades pre-market on NASDAQ at USD 0.8541, and the company reports Q4 2025 results on 27 Mar 2026. HUMA stock faces a clear earnings catalyst that could drive intraday volatility given the company’s negative EPS of -0.27 and heavy recent volume of 52,324,316 shares. Investors should watch revenue beats, trial updates for human acellular vessels, and cash-burn signals. We use company metrics, analyst consensus and technicals to frame likely market reactions and near-term trading scenarios.